https://www.ainvest.com/news/ascendis-pharma-15min-chart-shows-kdj-golden-cross-bullish-marubozu-pattern-2601/
Ascendis Pharma's 15min chart shows KDJ Golden Cross, bullish Marubozu pattern.
golden crossascendispharmachartshows
https://www.hl.co.uk/shares/shares-search-results/a/ascendis-pharma-as-adr/dividends
View Ascendis Pharma AS ADR dividend dates and history including final, interim and special dividends. Plus growth, cover and dividend yield.
dividend paymentshistorydatesascendispharma
https://www.pharmaceutical-technology.com/data-insights/transcon-il-2-beta-gamma-ascendis-pharma-net-present-value-2/
TransCon IL-2 beta/gamma is a recombinant protein commercialized by Ascendis Pharma, with a leading Phase II program in Human Papillomavirus (HPV) Associated...
net present valuerisk adjustedcurrentvaluation
https://endpoints.news/fda-pushes-back-ascendis-dwarfism-drug-decision-date-by-three-months/
Nov 26, 2025 - FDA extends review of Ascendis' TransCon CNP dwarfism treatment to Feb 2026, citing post-marketing study protocol. BioMarin's Voxzogo is only other approved...
fdapushesbackascendisdwarfism
https://finviz.com/quote.ashx?t=ASND&ta=1&p=d&ty=ea
ASND - Ascendis Pharma A/S ADR - Stock screener for investors and traders, financial visualizations.
asndascendispharmaadrearnings
https://www.lw.com/en/news/2024/09/latham-watkins-advises-ascendis-pharma-in-us150-million-royalty-financing
Multidisciplinary team represents the biopharmaceutical company in the royalty agreement with Royalty Pharma.
latham watkinsroyalty financingadvisesascendispharma
https://www.ainvest.com/news/ascendis-pharma-15min-chart-triggers-kdj-death-cross-bearish-marubozu-2601/
Ascendis Pharma's 15min chart triggers KDJ Death Cross, Bearish Marubozu.
death crossascendispharmacharttriggers
https://investorshangout.com/ascendis-pharma-faces-fda-review-delay-for-transcon-cnp-therapy-473408-/
Ascendis Pharma's TransCon CNP therapy faces an unexpected FDA review delay, pushing the decision to 2026. Learn about the implications and updates here.
transcon cnpascendispharmafacesfda
https://www.clinicaltrialsarena.com/news/newsascendis-reports-positive-result-during-phase-ii-trial-of-transcon-growth-hormone-4636373/
Biotechnology firm Ascendis Pharma has revealed the positive top-line results from its six-month Phase II paediatric trial of once-weekly TransCon Growth...
phase ii trialpositive resultascendisreportstranscon